Modulation of GABA A receptors by natural products and the development of novel synthetic ligands for the benzodiazepine binding site

Current Drug Targets

Volumn 12, Issue 11, 2011, Pages 1674-1688

  Nilsson, Jakob ^a   Sterner, Olov ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Benzodiazepine binding site; Flavonoids; Gaba; Pharmacophore model; Polyacetylenes; Receptor; Sar; Terpenes

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; ABSINTHOL; ANISATIN; BALDRINAL; BILOBALIDE; BORNEOL; CARNOSIC ACID; CARNOSOL; CICUTOXIN; CUNANIOL; DIAZEPAM; FLAVONOID; GALDOSOL; GINKGOLIDE B; GINSENOSIDE RC; ISOCURCUMENOL; MILTIRONE; OENANTHOTOXIN; PICROTOXIN; POLYACETYLENE DERIVATIVE; TANSHINONE I; TANSHINONE IIA; TERPENOID DERIVATIVE; THYMOL; THYMOQUINONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALERANONE; VALERENIC ACID; VALTRATE;

DRUG ACTIVITY; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; NONHUMAN; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW;

ANIMALS; BENZODIAZEPINES; BINDING SITES; BIOLOGICAL AGENTS; HUMANS; LIGANDS; RECEPTORS, GABA-A;

EID: 80054084047     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945011798109509     Document Type: Review

References (139)

1. Sieghart W. Structure, pharmacology, and function of GABAA receptor subtypes. Adv Pharmacol 2006; 54: 231-63.
2. Schofield PR, Darlison MG, Fujita N, et al. Sequence and functional expression of the GABAA receptor shows a ligand-gated receptor super-family. Nature 1987; 328: 221-7.
3. Barnard EA, Skolnick P, Olsen RW, et al. International Union of Pharmacology. XV. Subtypes of γ-aminobutyric acidA receptors: Classification on the basis of subunit structure and receptor function. Pharmacol Rev 1998; 50: 291-314.
4. Noda M, Takahashi H, Tanabe T, et al. Structural homology of Torpedo californica acetylcholine receptor subunits Nature 1983; 302: 528-32.
5. Langosch D, Thomas L, Betz H. Conserved quaternary structure of ligand-gated ion channels: the postsynaptic glycine receptor is a pentamer. Proc Natl Acad Sci USA 1988; 85: 7394-8.
6. Maricq AV, Peterson AS, Brake AJ, Myers RM, Julius D. Primary structure and functional expression of the 5HT3 receptor, a serotonin-gated ion channel. Science 1991; 254: 432-7.
7. Doble A, Martin IL. The GABAA/Benzodiazepine receptor as target for psychoactive drugs. Heidelberg: Springer-Verlag 1996.
8. Study RE, Barker JL. Diazepam and (−)-pentobarbital: fluctuation analysis reveals different mechanisms for potentiation of gamma- aminobutyric acid responses in cultured central neurons. Proc Natl Acad Sci USA 1981; 78: 7180-4.
9. Johnston GAR. GABAA receptor channel pharmacology. Curr Pharm Des 2005; 11: 1867-85.
10. Korpi ER, Grunder G, Luddens H. Drug interactions at GABAA receptors. Prog Neurobiol 2002; 67: 113-59.
11. Smith GB, Olsen RW. Functional domains of GABAA receptors. Trends Pharmacol Sci 1995; 16: 162-8.
12. Woods JH, Katz JL, Winger G. Benzodiazepines: Use, abuse, and consequences. Pharmacol Rev 1992; 44: 151-347.
13. Sigel E. Mapping of the benzodiazepine recognition site on GABAA receptors. Curr Top Med Chem 2002; 2: 833-9.
14. Gunther U, Benson J, Benke D, et al. Proc Natl Acad Sci USA 1995; 92: 7749-53.
15. Pritchett DB, Lüddens H, Seeburg PH. Type I and type II GABAA- benzodiazepine receptors produced in transfected cells. Science 1989; 245: 1389-92.
16. Rudolph U, Crestani F, Benke D, et al. Benzodiazepine actions mediated by specific gamma-aminobutyric acidA, receptor subtypes. Nature 1999; 401: 796-800.
17. Rudolph U, Crestani F, Möhler H. GABAA Receptor subtypes: dissecting their pharmacological functions. Trends pharmacol Sci 2001; 22: 188-94.
18. Buckingham J. Dictionary of Natural Products. London: Chapman and Hall 1994.
19. Hold KM, Sirisoma NS, Ikeda T, Narahashi T, Casida JE. α-Thujone (the active component of absinthe): γ-Aminobutyric acid type A receptor modulation and metabolic detoxification. Proc Natl Acad Sci USA 2000; 97: 3826-31.
20. Deiml T, Haseneder R, Zieglgansberger W, et al. α-Thujone reduces 5-HT3 receptor activity by an effect on the agonist-induced desensitization. Neuropharmacology 2004; 46: 192-201.
21. Lachenmeier DW, Walch SG. Absinthe-A Review. Crit Rev Food Sci 2006; 46: 365-77.
22. Priestley CM, Williamson EM, Wafford K, Sattelle DB. Thymol, a constituent of thyme essential oil, is a positive allosteric modulator of human GABAA receptors and a homo-oligomeric GABA receptor from Drosophila melanogaster. Br J Pharmacol 2003; 140: 1363-72.
23. Garcia DA, Bujons J, Vale C, Suñol C. Allosteric positive interaction of thymol with the GABAA receptor in primary cultures of mouse cortical neurons. Neuropharm 2006; 50: 25-35.
24. Garcia DA, Vendrell I, Galofre M, Suñol C. GABA released from cultured cortical neurons influences the modulation of t-[35S]butylbicyclophosphorothionate binding at the GABAA receptor: Effects of thymol. Eur J Pharm 2008; 600: 26-31.
25. Hosseinzadeh H, Parvardeh S. Anticonvulsant effects of thymoquinone, the major constituent of Nigella sativa seeds, in mice. Phytomedicine 2004; 11: 56-64.
26. Abdel-Fattah AM, Matsumoto K, Watanabe H. Antinociceptive effects of Nigella sativa oil and its major component, thymoquinone, in mice. Eur J Pharm 2000; 400: 89-97.
27. Nassiri-Asl M, Shariati-Rad S, Zamansoltani F. Anticonvulsant effects of aerial parts of Passiflora incarnata extract in mice: involvement of benzodiazepine and opioid receptors. BMC Complem Altern M 2007; 7: 1-6.
28. Granger RE, Campbell EL, Johnston GAR. (+)-And (−)-borneol: efficacious positive modulators of GABA action at human recombinant α1β2γ2L GABAA receptors. Biochem Pharmacol 2005; 69: 1101-11.
29. Van Beck TA, Bombardelli E, Morazzoni P, Peterlongo F. "Ginko biloba L". Fitoterapia 1998; 69: 195-244.
30. Major RT. The Ginko, the most ancient living tree. Science 1967; 157: 1270-3.
31. Kiewert C, Kumar V, Hildmann O, et al. Role of GABAergic antagonism in the neuroprotective effects of bilobalide. Brain Res 2007; 1128: 70-8.
32. Smith LY, Paramasivam V, Burdick A, et al. Inhibition of Amyloid-β Aggregation and Caspase-3 Activation by the Ginkgo biloba Extract EGb761. Proc Nat Acad Sci 2002; 99: 12197-202.
33. LeBars PL, Katz MM, Berman N, et al. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. J Amer Med Assoc 1997; 278: 1327-32.
34. Ernst E, Pittler, MH. Ginkgo biloba for Dementia: A systematic review of double-blind, placebo-controlled trials. Clin Drug Invest 1999; 17: 301-8.
35. DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG. Ginkgo biloba for Prevention of Dementia: A Randomized Controlled Trial. J Amer Med Assoc 2008; 300: 2253-62.
36. Snitz BE, O'Meara ES, Carlson MC, et al. Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. J Amer Med Assoc 2009; 302: 2663-70.
37. Jones FA, Chatterjee SS, Davies JA. Effects of bilobalide on amino acid release and electrophysiology of cortical slices. Amino Acids 2002; 22: 369-79.
38. Huang SH, Duke RK, Chebib M, et al. Bilobalide, a sesquiterpene trilactone from Ginkgo biloba, is an antagonist at recombinant α1β2γ2L GABAA receptors. Eur J Pharmacol 2003; 464: 1-8.
39. Huang SH, Duke RK, Chebib M, et al. Mixed antagonistic effects of bilobalide at ρ1 GABAC receptors. Neuroscience 2006; 137: 607-17.
40. Qian H, Pan Y, Zhu Y, Khalili P. Picrotoxin accelerates relaxation of GABAC receptors. Mol Pharmacol 2005; 67: 470-9.
41. Huang SH, Duke RK, Chebib M, et al. Ginkgolides, diterpene trilactones of Ginkgo biloba, as antagonists at recombinant alpha1beta2gamma2L GABAA receptors. Eur J Pharmacol 2004; 494: 131-8.
42. Ivic L, Sands TT, Fishkin N, et al. Terpene trilactones from Ginkgo biloba are antagonists of cortical glycine and GABAA receptors. J Biol Chem 2003; 278: 49279-85.
43. Shinozaki H, Ishida M, Kudo Y. Effects of anisatin on the GABA action in the crayfish neuromuscular junction. Brain Res 1981; 222: 401-5.
44. Kudo Y, Oka J, Yamada K. Anisatin, a potent GABA antagonist, isolated from Illicium anisatum. Neurosci Lett 1981; 25: 83-8.
45. Ha JH, Lee KY, Choi HC, et al. Modulation of radioligand binding to the GABAA-benzodiazepine receptor complex by a new component from Cyperus rotundus. Biol Pharm Bull 2002; 25: 128-30.
46. Houghton PJ. The scientific basis for the reputed activity of Valerian. J Pharm Pharmacol 1999; 51: 505-12.
47. Bounthanh C, Bergmann C, Beck JP, Haag-Berrurier M, Anton R. The action of valepotriates on the synthesis of DNA and proteins of cultured hepatoma cells. Planta Med 1983; 49: 138-42.
48. Bos R, Woerdenbag HJ, Hendriks H, et al. Analytical aspects of phytotherapeutic Valerian preparations. Phytochem Anal 1996; 7: 143-51.
49. Taibi DM, Landis CA, Petry H, Vitiello MV. A systematic review of valerian as a sleep aid: safe but not effective. Sleep Med Rev 2007; 11: 209-30.
50. Trauner G, Khom S, Baburin I, et al. Modulation of GABAA receptors by valerian extracts is related to the content of valerenic acid. Planta Med 2008; 74: 19-24.
51. Yuan CS, Mehendale S, Xiao Y, et al. The gamma-aminobutyric acidergic effects of valerian and valerenic acid on rat brainstem neuronal activity. Anesth Analg 2004; 98: 353-8.
52. Khom S, Timin E, Hohaus A, et al. Valerenic acid potentiates and inhibits GABAA receptors: Molecular mechanism and subunit specificity. Neuropharmacology 2007; 53: 178-87.
53. Benke D, Barberis A, Kopp S, et al. GABAA receptors as in vivo substrate for the anxiolytic action of valerenic acid, a major constituent of valerian root extracts. Neuropharmacology 2009; 56: 174-81.
54. Dietz BM, Mahady GB, Pauli GF, Farnsworth NR. Valerian extract and valerenic acid are partial agonists of the 5-HT5a receptor in vitro. Mol Brain Res 2005; 138: 191-7.
55. Lacher SK, Mayer R, Sichardt K, Nieber K, Müller CE. Interaction of valerian extracts of different polarity with adenosine receptors: Identification of isovaltrate as an inverse agonist at A1 receptors. Biochem Pharm 2007; 73: 248-58.
56. Gao YG, Song YM, Yang YY, Liu WF, Tang JX. Pharmacology of tanshinone. Yao Xue Xue Bao 1979; 14: 75-82.
57. Lee CM, Wong HN, Chui KY, et al. Miltirone, a central benzodiazepine receptor partial agonist from a Chinese medicinal herb Salvia miltiorrhiza. Neurosci Lett 1991; 127: 237-41.
58. Kim DH, Jeon SJ, Jung JW, et al. Tanshinone congeners improve memory impairments induced by scopolamine on passive avoidance tasks in mice. Eur J Pharm 2007; 574: 140-7.
59. Kavvadias D, Monschein V, Sand P, Riederer P, Schreier P. Constituents of sage Salvia officinalis L., with in vitro affinity to human brain benzodiazepine receptor. Planta Med 2003; 69: 113-7.
60. 35S]thionate binding to chloride channel of rat cerebrocortical membranes in vitro. Neurosci Lett 1992; 135: 224-6.
61. Choi SE, Choi S, Lee JH, et al. Effects of ginsenosides on GABAA receptor channels expressed in Xenopus oocytes. Arch Pharm Res 2003; 26: 28-33.
62. Cha HY, Park JH, Hong JT, et al. Anxiolytic-like effects of ginsenosides on the elevated plus-maze model in mice. Biol Pharm Bull 2005; 28: 1621-5.
63. Clark JB. Effect of a polyacetylenic fish poison on the oxidative phosphorylation of rat liver. Biochem Pharmacol 1969; 18: 73-83.
64. Quilliam JP, Stables R. Convulsant effects of cunaniol, a polyacetylenic alcohol isolated from the plant Clibadium sylvestre, on frogs and mice. Pharmacol Res Comm 1969; 1: 7-14.
65. Curtis DR, Johnston GAR. Convulsant alkaloids. Neuropoisons 1974; 2: 207-48.
66. Uwai K, Ohashi K, Takaya Y, et al. Virol A, a toxic trans- polyacetylenic alcohol of Cicuta virosa, selectively inhibits the GABA-induced Cl(−) current in acutely dissociated rat hippocampal CA1 neurons. Brain Res 2001; 889: 174-80.
67. Schep LJ, Slaughter RJ, Becket G, Beasley DMG. Poisoning due to water hemlock. ClinToxicol Phila 2009; 47: 270-8.
68. Uwai K, Ohashi K, Takaya Y, et al. Exploring the structural basis of neurotoxicity in C(17)-polyacetylenes isolated from water hemlock. J Med Chem 2000; 43: 4508-15.
69. Appendino G, Pollastro F, Verotta L, et al. Polyacetylenes from Sardinian Oenanthe fistulosa: A Molecular Clue to risus sardonicus. J Nat Prod 2009; 72: 962-5.
70. Baur R, Simmen U, Senn M, Séquin U, Sigel E. Novel plant substances acting as β subunit isoform-selective positive allosteric modulators of GABAA receptors. Mol Pharmacol 2005; 68: 787-92.
71. Senn M, Gunzenhauser S, Brun R, Séquin U. Antiprotozoal polyacetylenes from the Tanzanian medicinal plant Cussonia zimmermannii. J Nat Prod 2007; 70: 1565-9.
72. Haenen G, Bast A. Nitric oxide radical scavenging of flavonoids. Methods in enzymology 1999; 301: 409-503.
73. Havsteen BH. The biochemistry and medical significance of the flavonoids. Pharmacol Ther 2002; 96: 67-202.
74. Aherne SA, O'Brian NM. Dietary flavanols: Chemistry, food content, and metabolism. Nutrition 2002; 18: 75-81.
75. Heim KE, Tagliaferro AR, Bobilya DJ. Flavonoid antioxidants: Chemistry, metabolism and structure-activity relationships. J Nutr Biochem 2002; 13: 572-84.
76. Le Marchand L. Cancer preventive effects of flavonoids: A review. Biomed Pharmacother 2002; 56: 296-301.
77. Woodman OL, Chan EC. Vascular and anti-oxidant actions of flavonols and flavones. Clin Exp Pharmacol Physiol 2004; 31: 786-90.
78. Harborne JB. Nature, distribution and function of plant flavonoids. Prog Clin Biol Res 1986; 213: 15-24.
79. Harborne JB, Williams CA. Advances in flavonoid research since 1992. Phytochemistry 2000; 55: 481-504.
80. Grayer RJ, Harborne JB. A survey of antifungal compounds from higher plants, 1982-1993. Phytochemistry 1994; 37: 19-42.
81. Luk KC, Stern L, Weigele M, O'Brian RA, Spirst N. Isolation and identification of "diazepam-like" compounds in bovine brain. J Nat Prod 1983; 46: 852-61.
82. Nielsen M, Frokjaer S, Braestrup C. High affinity of naturally- occuring biflavonoid, amentoflavone, to brain benzodiazepine receptors in vitro. Biochem Pharmacol 1988; 37: 3285-7.
83. Hansen RS, Paulsen I, Davies M. Determinants of amentoflavone interaction at the GABAA receptor. Eur J Pharm 2005; 519: 199-207.
84. Gutmann H, Bruggisser R, Schaffner W, et al. Transport of amentoflavone across the blood-brain barrier in vitro. Planta Med 2000; 68: 804-7.
85. Butterweck V, Narstedt A, Evans J, et al. In vitro receptor screening of pure constituents of St. John's wort reveals novel interactions with a number of GPCRs. Psychopharmacology 2002; 162: 193-202.
86. Linde K, Ramirez G, Mulrov C, et al. St John's wort for depression-an overview and meta-analysis of randomised clinical trials, Brit Med J 1996; 313: 253-8.
87. Volz HP. Kava-kava extract WS 1490 versus placebo in anxiety disorders-a randomized placebo-controlled 25-week outpatient trial. Pharmacopsychiatry 1997; 30: 1-5.
88. Erdelmeier CAJ. Hyperforin, possibly the major non-nitrogenous secondary metabolite of Hypericum perforatum L. Pharmacopsychiatry 1998; 31: 2-6.
89. Chatterjee SS, Noeldner M, Koch E, Erdelmeier C. Antidepressant activity of Hypericum perforatum and hyperforin: the neglected possibility. Pharmacopsychiatry 1998; 31: 7-15.
90. Chatterjee SS, Bhattacharya SK, Wonnemann M, Singer A, Müller WE. Hyperforin as a possible antidepressant component of Hypericum extracts. Life Sci 1998; 63: 499-510.
91. Leuner K, Kazanski V, Müller M, et al. Hyperforin-a key constituent of St. John's wort specifically activates TRPC6 channels. FASEB J 2007; 21: 4101-11.
92. Harborne JB, Mabry TJ. Flavanoids. Advances in research since 1986. London: Chapman and Hall 1994.
93. Svenningsen AB, Madsen KD, Liljefors T, et al. Biflavones from Rhus species with affinity for the GABAA/benzodiazepine receptor. J Ethnopharm 2006; 103: 276-80.
94. Medina JH, Paladini AC, Wolfmann C, et al. Chrysin (5,7-Di-OH-flavone), a naturally-occuring ligand for the benzodiazepine receptors, with anticonvulsant properties. Biochem Pharmacol 1990; 40: 2227-31.
95. Paladini AC, Marder M, Viola H, et al. Flavonoids and the central nervous system; from forgotten factors to potent anxiolytic compounds. J Pharm Pharmacol 1999; 51: 519-26.
96. Wolfman C, Viola H, Paladini A, Dajas F, Medina JH. Possible anxiolytic effects of chrysin, a central benzodiazepine receptor ligand isolated from Passiflora Coerulea. Pharmacol Biochem Behav 1994; 47: 1-4.
97. Brown EW, Hurd NS, McCall S, Ceremuga TE. Evaluation of the anxiolytic effects of chrysin, a Passiflora incarnata extract, in the laboratory rat. AANA 2007; 75: 333-7.
98. Viola H, Wasowski C, Levi de Stein M, et al. Apigenin, a component of Matricaria recutita flowers, is a central benzodiazepine receptors-ligand with anxiolytic effects. Planta Med 1995; 61: 213-6.
99. Avallone R, Zanoli P, Puia G, et al. Pharmacological profile of apigenin, a flavonoid isolated from Matricaria chamomilla, Biochem Pharmacol 2000; 59: 1387-94.
100. Johnston GAR, Hanrahan JR, Chebib M, Duke RK, Mewett KN. Modulation of ionotropic GABA receptors by natural products of plant origin. Adv Pharmacol 2006; 54: 285-315.
101. Kubo M, Kimura Y, Odani T, Tani T, Namba K. Studies on Scutellariae radix. Part II: the antibacterial substance. Planta Med 1981; 43: 194-201.
102. Kimuya Y, Kubo M, Tani T, Arichi S, Okuda H. Studies on Scutellariae radix. Part IV. Effects on lipid peroxidation in rat liver. Chem Pharm Bull Tokyo 1981; 29: 2610-7.
103. Hui KM, Huen MS, Wang HY, et al. Anxiolytic effect of wogonin, a benzodiazepine receptor ligand isolated from Scutellaria baicalensis Georgi. Biochem Pharmacol 2002; 64: 1415-24.
104. Wang F, Huen MSY, Tsang SY, Xue H. Neuroactive flavonoids interacting with GABAA receptor complex. Curr Drug Targets 2005; 4: 575-85.
105. Park HG, Yoon SY, Choi JY, et al. Anticonvulsant effect of wogonin isolated from Scutellaria baicalensis. Eur J Pharm 2007; 574: 112-9.
106. Huen MS, Leung JW, Ng W, et al. 5,7-Dihydroxy-6- methoxyflavone, a benzodiazepine site ligand isolated from Scutellaria baicalensis Georgi, with selective antagonistic properties. Biochem Pharmacol 2003; 66: 125-32.
107. Kim DH, Jeon SJ, Son KH, et al. The ameliorating effect of oroxylin A on scopolamine-induced memory impairment in mice. Neurobiol Learn Mem 2007; 87: 536-46.
108. Liao JF, Wang HH, Chen MC, Chen CC, Chen CF. Benzodiazepine binding site-interactive flavones from Scutellaria baicalensis root. Planta Med 1998; 64: 571-2.
109. Liao JF, Hung WY, Chen CF. Anxiolytic-like effects of baicalein and baicalin in the Vogel conflict test in mice. Eur J Pharm 2003; 464: 141-6.
110. Wang H, Hui KM, Chen Y, et al. Structure-activity relationships of flavonoids, isolated from Scutellaria baicalensis, binding to benzodiazepine site of GABAA receptor complex. Planta Med 2002; 68: 1059-62.
111. Huen MS, Hui KM, Leung JW, et al. Naturally occurring 2'- hydroxyl-substituted flavonoids as high-affinity benzodiazepine site ligands. Biochem Pharmacol 2003; 66: 2397-407.
112. Wasowski C, Marder M, Viola H, Medina JH, Paladini AC. Isolation and identification of 6-methylapigenin, a competitive ligand for the brain GABAA receptors, from Valeriana wallichii. Planta Med 2002; 68: 934-6.
113. Marder M, Viola H, Wasowski C, et al. 6-Methylapigenin and hesperidin: new valeriana flavonoids with activity on the CNS. Pharmacol Biochem Behav 2003; 75: 537-45.
114. Fernandez S, Wasowski C, Paladini AC, Marder M. Sedative and sleep-enhancing properties of linarin, a flavonoid-isolated from Valeriana officinalis. Pharmacol Biochem Behav 2004; 77: 399-404.
115. Fernandez S, Wasowski C, Paladini AC, Marder M. Synergistic interaction between hesperidin, a natural flavonoid, and diazepam. Eur J Pharm 2005; 512: 189-98.
116. Fernandez S, Wasowski C, Leonardo M, et al. Central nervous system depressant action of flavonoid glycosides. Eur J Pharm 2006; 539: 168-76.
117. Leonardo M, Wasowski C, Paladini AC, Marder M. Opoid receptors are involved in the sedative effects of hesperidin as well as in its potentiation with benzodiazepines. Eur J Pharm 2008; 580: 306-13.
118. Perry EK, Pickering AT, Wang WW, Houghton PJ, Perry NS. Medicinal plants and Alzheimer's disease: From ethnobotany to phytotherapy. J Pharm Pharmacol 1999; 51: 527-34.
119. Perry NS, Howes MJ, Houghton P, Perry E. Why sage may be a wise memory remedy: Effects of salvia on the nervous system. Med Arom Plants Indust Profiles 2000; 14: 207-23.
120. Kavvadias D, Sand P, Youdim KA, et al. The flavone hispidulin, a benzodiazepine receptor ligand with positive allosteric properties, traverses the bloodbrain barrier and exhibits anti-convulsive effects. Br J Pharmacol 2004; 142: 811-20.
121. Viola H, Wasowski C, Marder M, et al. Sedative and hypnotic properties of Salvia guaranitica and of its active principle, cirsiliol. Phytomedicine 1997; 4: 47-52.
122. Shen XL, Nielsen M, Witt MR, et al. Inhibition of [methyl- 3 H]diazepam binding to rat brain membranes in vitro by dinatin and skrofulein. Zhongguo Yao li Xue bao 1994; 15: 385-8.
123. Shen XL, Witt MR, Nielsen M, Sterner O. Inhibition of [3H]flunitrazepam binding to rat brain membranes in vitro by puerarin and daidzein. Zhongguo Yao li Xue bao 1996; 31: 59-62.
124. Haffely W, Kybura E, Gerecke M, Mohler H. Recent advances in the molecular pharmacology of benzodiazepine receptors and the structural-activity relationships of their agonists and antagonists. Adv Drug Res 1985; 14: 165-322.
125. Dekermendijan K, Kahnberg P, Witt M, et al. Structure-activity relationships and molecular modeling analysis of flavonoids binding to the benzodiazepine site of the rat brain GABAA receptor complex. J Med Chem 1999; 42: 4343-50.
126. Kahnberg P, Lager E, Rosenberg C, et al. Refinement and evaluation of a pharmacophore model for flavone derivatives binding to the benzodiazepine site of the GABAA receptor. J Med Chem 2002; 45: 4188-201.
127. Zhang W, Koehler KF, Zhang P, Cook JM. Development of a comprehensive pharmacophore model for the benzodiazepine receptor. Drug Des Discovery 1995; 12: 193-248.
128. Borea PA, Gilli G, Bertolasi V, Ferretti V. Stereochemical features controlling binding and intrinsic activity properties of benzodiazepine-receptor ligands. Mol Pharmacol 1987; 31: 334-44.
129. He X, Huang Q, Ma C, et al. Pharmacophore/receptor models for GABAA/BzR α2β3γ2, α3β3γ2 and α4β3γ2 recombinant subtypes. Including volume analysis and comparison to α1β3γ2, α5β3γ2 and α6β3γ2 subtypes. Drug Des Discovery 2000; 17: 131-71.
130. Huang Q, He X, Ma C, et al. Pharmacophore/Receptor Models for GABAA/BzR Subtypes α1β3γ2, α5β3γ2, and α6β3γ2, via a comprehensive ligand-mapping approach. J Med Chem 2000; 43: 71-95.
131. Gontier A, Nilsson J, Nielsen M, Sterner O, Liljefors T. Unpublished work.
132. Marder M, Paladini AC. GABAA-Receptor ligands of flavonoid structure. Curr Top Med Chem 2002; 2: 853-67.
133. 3H]muscimol binding sites three-fold in rat forebrain membranes in vitro, by allosterically increasing the affinities of low-affinity sites. Neurochem Res 1999; 24: 1593-602.
134. Kahnberg P, Howard MH, Liljefors T, et al. The use of a pharmacophore model for identification of novel ligands for the benzodiazepine binding site of the GABAA receptor. J Mol Graphics and Modell 2004; 23: 253-61.
135. Lager E, Andersson P, Nilsson J, et al. 4-Quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABAA receptors. Synthesis, pharmacology and pharmacophore modelling. J Med Chem 2006; 49: 2526-33.
136. Lager E, Nilsson J, Østergaard Nielsen E, et al. Affinity of 3-acyl substituted 4-quinolones at the benzodiazepine site of GABAA receptors. Bioorg Med Chem 2008; 16: 6936-48.
137. Nilsson J. The GABAA receptors as targets for novel heterocyclic compounds. PhD Thesis. Lund: Lund University May 2008.
138. Hiley CR, Hoi PM. Oleamide: a fatty acid amide signaling molecule in the cardiovascular system? Cardiovasc Drug Rev 2007; 25: 46-60.
139. Belelli D, Lambert JJ. Neurosteroids: endogenous regulators of the GABA(A) receptor. Nat Rev Neurosci 2005; 6: 565-75.